title: REAL-LIFE STUDY IN DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE IMPLANT: The Reldex Study.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of intravitreal implant of dexamethasone (Ozurdex) in diabetic macular edema in real-life practice.
  
  
  METHODS
  In this bicentric retrospective study, the authors reviewed 128 eyes of 89 patients. Main outcome measures included changes in best-corrected visual acuity, central macular thickness, time to retreatment, and incidence of adverse effects. Linear mixed-effects models were used to study changes in best-corrected visual acuity and central macular thickness over the 3-year follow-up.
  
  
  RESULTS
  Best-corrected visual acuity increased by a mean of 3.6 letters at Month 2 (P = 0.005), 4.2 letters at Month 12 (P = 0.006), 5.3 at Month 24 (P = 0.007), and 9.5 letters at Month 36 (P = 0.023). The proportion of eyes achieving at least a 15-letter improvement from baseline was 25.4% at Month 36. Central macular thickness decreased from 451 μm to 289 μm at Month 2 (P < 0.001), 370 μm at Month 12 (P < 0.001), 377 μm at Month 24 (P = 0.004), and 280 μm at Month 36 (P = 0.001). A mean of 3.6 injections were administered over the 3-year follow-up. Ten percent of eyes developed a transient increase in intraocular pressure (IOP ≥ 25 mmHg), and cataract was removed from 47% of phakic eyes.
  
  
  CONCLUSIONS
  This large case series study showed favorable 3-year outcomes when using Ozurdex to treat diabetic macular edema. Intravitreal Ozurdex provides substantial long-term benefits in the treatment of diabetic macular edema in real-life.
authors.affiliation: *Department of Ophthalmology, Croix-Rousse University Hospital, Hospices Civils de Lyon, UMR-CNRS 5510 Matéis, University of Medicine Lyon 1, Lyon, France; †Department of Ophthalmology, Desgenettes Military Hospital, Lyon, France; and ‡French Military Health Service Academy, Val de Grâce, Paris, France.
authors.forename: Ariane
authors.initials: A
authors.lastname: Malclès
authors.forename: Corinne
authors.initials: C
authors.lastname: Dot
authors.forename: Nicolas
authors.initials: N
authors.lastname: Voirin
authors.forename: Émilie
authors.initials: É
authors.lastname: Agard
authors.forename: Anne-Laure
authors.initials: AL
authors.lastname: Vié
authors.forename: David
authors.initials: D
authors.lastname: Bellocq
authors.forename: Philippe
authors.initials: P
authors.lastname: Denis
authors.forename: Laurent
authors.initials: L
authors.lastname: Kodjikian
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D003692:Delayed-Action Preparations; D003907:Dexamethasone / Q000008:administration & dosage*; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D004343:Drug Implants; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D007429:Intraocular Pressure; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D014792:Visual Acuity
chemical_list: D000893:Anti-Inflammatory Agents; D003692:Delayed-Action Preparations; D004343:Drug Implants; D005938:Glucocorticoids; D003907:Dexamethasone